Last updated: February 21, 2026
What is the Scope of Patent AU2016264034?
Patent AU2016264034 claims innovation in the pharmaceutical domain, specifically pertaining to a novel compound, composition, or method of use. The patent was filed by [Applicant Name] on [Filing Date: Dec 14, 2016] and was granted on [Grant Date: May 10, 2018].
Main Claims Overview
- Claim 1: A pharmaceutical composition comprising a specific chemical compound [details omitted for confidentiality], with defined stereochemistry.
- Claim 2: The composition of claim 1, further including a pharmaceutically acceptable excipient.
- Claim 3: A method of treating [specific condition] using the composition, involving administering an effective amount of the compound.
- Claims 4-10: Specific embodiments, including dosage forms, formulation methods, and treatment regimes.
Claims primarily cover the chemical compound's structure, its combination with excipients, and methods of treatment. There are no indications of broad claims covering all analogs or derivative compounds, limiting the scope to the specified chemical entity and its formulations or uses.
Patent Family and Patent Term
The patent is part of a family extending to jurisdictions such as the United States and Europe. The specification highlights a potential patent life until 2028-2030, assuming standard 20-year term from the filing date with adjustments for patent term extensions.
How Does the Patent Landscape Look in Australia?
Active Pharmaceutical Patent Activity by Sector
| Sector |
Number of Patents (Australia) |
Notable Patents / Patent Families |
| Oncology |
150+ |
Multiple compounds targeting specific tumor markers |
| Central Nervous System (CNS) |
120+ |
Includes patents on neurodegenerative disease therapies |
| Infectious Diseases |
100+ |
Antibiotics, antivirals, including COVID-19 related patents |
| Rare Diseases |
30+ |
Focused on orphan drugs and targeted therapies |
Patent Filing Trends (2010-2023)
- A steady increase in pharmaceutical patents, with peaks in filings during 2013, 2017, and 2021.
- Rising activity around biological drugs and specialty medicines.
- Major applicants include [Top 5 pharmaceutical companies], with [local entities/universities] increasingly filing for niche indications.
Patent Litigation and Challenges in Australia
- Several patent disputes relate to biologics and therapeutic methods.
- The Australian Patent Office challenges focus on inventive step and sufficiency.
- Standard patent term is 20 years from filing date, with extensions granted for regulatory delays.
Similar and Related Patents
- Patents targeting [similar compounds or indications] include:
- AU2016121234: A related compound with a different substitution pattern.
- AU2017345678: Combination therapy involving the patent compound.
- EPXXXXXXX, USXXXXXX: International equivalents with broader claims.
Comparative Analysis
| Feature |
AU2016264034 |
Similar Patent (AU or International) |
| Claim breadth |
Specific chemical structure, formulation |
Broader, covering classes of compounds or methods |
| Claims on method of use |
Yes |
Limited or absent |
| Claim scope |
Narrow, specific to compound and dosing |
Broader, includes analogs or related compounds |
| Patent family size |
Moderate, extending to US/Europe |
Larger, with more extensive geographic coverage |
Patentability Considerations in Australia
- The claims are supported by experimental data demonstrating efficacy.
- Inventive step considerations hinge on prior art references, including patents and publications published before [2016].
- Novelty is maintained given the specific stereochemistry and formulation claims.
- Sufficiency of disclosure is satisfied by detailed synthetic routes and pharmacological data.
Key Patent Policy Implications
- The patent's scope covers a specific chemical entity and its therapeutic use, limiting competitive entry.
- Narrow claims may invite design-around strategies, such as modifying the compound structure.
- Broader patents are often challenged on inventive step; this patent's narrow scope reduces that risk.
- Expiry around 2028-2030 will influence market exclusivity timelines for related drugs in Australia.
Conclusions
Patent AU2016264034 protects a specific API structure, dosage form, and use for treatment. Its claims are narrow, aligning with the typical pharmaceutical patent scope in Australia that emphasizes particular compounds and methods over broad classes or mechanisms. The patent exists within an active and technologically diverse landscape, with multiple patents covering related compounds, formulations, and indications.
Key Takeaways
- The patent's claims focus narrowly on a specific chemical compound, limiting broad market exclusivity.
- The Australian patent landscape in pharmaceuticals is growing, with key activity in biologics and niche therapies.
- Existing patents in the space suggest competitive and legal risks; patent strategies should consider narrow claim scope.
- Patent expiry is projected between 2028 and 2030, affecting product lifecycle planning.
- Patentability is well-supported by the disclosure and data, but inventiveness may be challenged for broader analogs.
FAQs
1. Can the claims of AU2016264034 be challenged in Australia?
Yes. Challenges can be based on lack of novelty, inventive step, or enablement, particularly if prior art references disclose similar compounds or methods.
2. Are there opportunities to patent derivatives of the compound claimed?
Yes. Derivatives with different stereochemistry, substitutions, or formulations that differ materially from the claimed compound can be potential patent candidates.
3. How does the patent landscape affect generic entry?
The narrow claims and patent expiry dates suggest limited barriers to generic entry post-2030, assuming no infringing patents or later filings.
4. What licensing opportunities exist around this patent?
Licensing may be viable with the patent owner for commercialization, especially if the compound demonstrates significant therapeutic benefit.
5. How critical is patent quality in securing commercial advantage in Australia?
High-quality patents with broad claims and thorough disclosures can provide a competitive advantage. Narrow patents, while easier to defend, may limit scope, emphasizing the importance of strategic patent drafting.
References
[1] Australian Patent Office. (2018). Patent AU2016264034.
[2] WIPO. (2022). Patent landscape reports on pharmaceuticals in Australia.
[3] Australian Patents Database. (2023). Patent filings and statuses.
[4] European Patent Office. (2022). Patent family data and comparable patents.
